Farallon Capital Management, in latest filing, disclosed that it initiated a position in Sycamore Networks, Inc. (OTCMKTS:SCMR), reporting ownership of......
(read more)January 14 - Hedge Funds, News - Comments
According to the American Cancer Society, more than 60,000 new cases of thyroid cancer will be diagnosed in the U.S., and about 1,850 people are expected......
(read more)September 23 - News - Comments
Blazing. Sizzling. On fire. They all describe Celgene Corporation (NASDAQ:CELG) pretty well these days. With all of the heat generated by this biotech......
(read more)September 16 - News - Comments
At the moment, there are a multitude of metrics shareholders can use to monitor stocks. A pair of the most useful are hedge fund and insider trading sentiment......
(read more)September 10 - News - Comments
They say that bad news comes in threes. I’m not sure if there’s a similar saying for good news, but for Celgene Corporation (NASDAQ:CELG)......
(read more)September 5 - News - Comments
Another domino has fallen in the world of biotech. Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) is being scooped up by Tokyo-based Otsuka Pharmaceuticals......
(read more)September 5 - News - Comments
Editor’s Note: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Amgen, Inc. (NASDAQ:AMGN), Onyx Pharmaceuticals, Inc. (......
(read more)September 5 - News - Comments
With the SPDR S&P Biotech Index up 35% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into......
(read more)September 1 - News - Comments
Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case......
(read more)August 27 - News - Comments
After a second offer, Amgen, Inc. (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), a maker of drugs to fight cancer among other diseases,......
(read more)August 27 - News - Comments
As I’m sure you’ve probably heard by now, Amgen, Inc. (NASDAQ:AMGN) agreed to purchase Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) for $125......
(read more)August 26 - News - Comments
Although we don’t believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes — just in case......
(read more)August 26 - News - Comments
A finale has at last arrived for the biotech drama of summer 2013. Amgen, Inc. (NASDAQ:AMGN) announced yesterday that it will buy Onyx Pharmaceuticals......
(read more)August 26 - News - Comments
Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) a buy? In the 21st century investor’s toolkit, there are tons of metrics market participants can......
(read more)August 26 - News - Comments
Although we don’t believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes — just in case......
(read more)August 26 - News - Comments
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) investors: listen up. In the 21st century investor’s toolkit, there are tons of metrics shareholders can use......
(read more)August 26 - News - Comments
Should you be crazy about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)? In the financial world, there are dozens of gauges shareholders can use to analyze......
(read more)August 26 - News - Comments
At the end of June, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that it had rejected an offer from Amgen, Inc. (NASDAQ:AMGN) that valued the......
(read more)August 24 - News - Comments
If you were to ask many investors, hedge funds are assumed to be useless, old investment tools of a period lost to current times. Although there are more......
(read more)August 23 - News - Comments
There’s been plenty of buzz lately about the continuing saga of the possible buyout of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) by Amgen, Inc. (......
(read more)August 23 - News - Comments
Earlier this month, biotech powerhouse Celgene Corporation (NASDAQ:CELG) announced that the European Commission approved the combinational therapy of......
(read more)August 22 - News - Comments
Biotech’s the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling......
(read more)August 19 - News - Comments
The buyout drama surrounding cancer drug maker Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is really beginning to heat up, and it’s offering investors......
(read more)August 16 - News - Comments
With the SPDR S&P Biotech Index up 40% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the......
(read more)August 12 - News - Comments
Over the past year, the battle over cancer treatments has heated up considerably. Big pharma companies such as Amgen, Inc. (NASDAQ:AMGN), Pfizer Inc. (......
(read more)August 7 - News - Comments
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), already quite expensive, spiked higher since takeover rumors surfaced in early July. But can a deal give......
(read more)August 6 - News - Comments
In the last couple of months, we saw two big offers being made – and rejected – in the biotech sector. Both times, the companies that rejected......
(read more)August 5 - News - Comments
Multiple myeloma is a cancer of plasma cells, a type of white blood cell present in bone marrow. This cancer can lead to abnormally high calcium levels......
(read more)July 26 - News - Comments
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout. Reportedly, four......
(read more)July 24 - News - Comments
We have a bona fide biotech soap opera going on these days. Spurned love. Possible romance. Disgruntled suitor. And, of course, the unknown villain. In......
(read more)July 24 - News - Comments
Global biotechnology industry revenue is expected to reach $262 billion this year showing growth of around 12.7% year over year. This industry has witnessed......
(read more)July 22 - News - Comments
Biotech’s the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling......
(read more)July 22 - News - Comments
In an industry where buyouts are commonplace and small-cap biotechs burn through cash rapidly, optimizing operating cash flow can be essential to a company......
(read more)July 19 - News - Comments
The “people familiar with the matter” are out in full force spouting off about who’s bidding for Onyx Pharmaceuticals, Inc. (NASDAQ......
(read more)July 19 - News - Comments
Celgene Corporation (NASDAQ:CELG) has emerged as the leading treatment provider for blood cancer. The company value has almost doubled in the last year......
(read more)July 19 - News - Comments
Celgene Corporation (NASDAQ:CELG) surged 7% on Thursday, July 11, 2013 on news that the Phase III trials of Revlimid /dexamethasone combination showed......
(read more)July 18 - News - Comments
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable......
(read more)July 18 - News - Comments
Buyout! The word gets biotech investors’ blood flowing and their hearts racing. Mere rumors that a biotech stock could get bought out can send shares......
(read more)July 17 - News - Comments
Good news seems to find its way to Celgene Corporation (NASDAQ:CELG)‘s door frequently these days. The company announced positive results today......
(read more)July 11 - News - Comments
Recently Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) rejected a $10 billion takeover offer from Amgen, Inc. (NASDAQ:AMGN). However, after that it hired an......
(read more)July 10 - News - Comments
Cancer-drug maker Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) recently rejected an $8.7 billion unsolicited acquisition offer from Amgen, Inc. (NASDAQ:......
(read more)July 10 - News - Comments
